ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours.
The scientific results that form the basis of the proof of concept in animal models show a strong therapeutic effect on par with leading treatments on the market. The data will be presented the 30th of November at the Virus-Like Particle & Nano-Particle Vaccines meeting in Singapore under the title ‘A novel VLP-display technology enables induction of protective antibody responses directed against human HER2 in a transgenic mouse model of spontaneous breast cancer’ and has also been submitted for publication in a renowned, peer-reviewed scientific journal with expected publication later in 2017.
The idea to use a vaccine treatment against non-infectious diseases such as cancer or allergy is not new. However, up until now it has been very difficult in cancer to overcome the body’s immune response and show strong therapeutic efficiency with modern so-called subunit vaccines. By adding a virus-like structure to the substance to trigger the immune system in a specific way, AdaptVac’s technology is ideally suited for a rapid conversion of a broad range of previously inefficient subunit vaccines to efficient treatments. AdaptVac’s project portfolio currently consists of two lead projects: the breast cancer project and one undisclosed infectious disease project.
AdaptVac will now initiate discussions with large pharmaceutical companies regarding a license or collaboration agreement for the clinical development of the project.